- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
+0.60| Last Update: 05/22/13 - 4:04 PM EDT |
| Volume: 608,852 |
| YTD Performance: -23.45% |
| Open: $43.82 |
| Previous Close: $43.91 |
| 52 Week Range: $43.16 - $65.93 |
| Oustanding Shares: 30,347,939 |
| Market Cap: 1,346,234,574 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $0.60 | $0.54 | $2.29 | $2.70 |
| Number of Analysts | 11 | 10 | 13 | 11 |
| High Estimate | $0.63 | $0.57 | $2.40 | $2.95 |
| Low Estimate | $0.55 | $0.50 | $2.15 | $2.55 |
| Prior Year | $0.55 | $0.54 | $2.11 | $2.29 |
| Growth Rate (Year over Year) | 8.60% | -0.93% | 8.38% | 18.10% |
Vitamin Shoppe downgraded at BofA/MerrillVSI was downgraded from Neutral to Underperform, Bank of America/Merrill Lynch said. Estimates also cut, as the company is facing increased competition. $40 price target.
Vitamin Shoppe upgraded at WedbushShares of VSI were upgraded to Outperform from Neutral, said Sterne Agee. Channel checks are strong and the stock has an attractive valuation. Price target goes to $62.
Digging into the nutrition food chain turns up this solid Dutch-based name that flies under the radar.
Use quiet April blah time to gauge business environment.
Vitamin Shoppe downgraded at BofA/MerrillVSI was downgraded from Buy to Neutral, Bank of America/Merrill Lynch said. $55 price target. Company may be facing increased competition.
Vitamin Shoppe numbers reduced at Credit SuisseShares of VSI now seen reaching $65, according to Credit Suisse. Estimates also cut, as the company is facing cost headwinds. Outperform rating.
Vitamin Shoppe numbers raised at JP Morgan Shares of VSI now seen reaching $73, according to JP Morgan. Estimates also increased, as the company is accelerating square footage growth and improving merchandising. Overweight rating.
Savvy investors identify society's pain points as a way to spot market opportunities.
Solid performers Dunkin' Donuts and Vitamin Shoppe are scheduled to report their quarterly results this week.
Vitamin Shoppe upgraded at BofA/MerrillVSI was upgraded from Neutral to Buy, Bank of America/Merrill Lynch said. $67 price target. Company can sustain healthy growth.